Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

JELINEK, Tomas (203 Czech Republic, guarantor), Tereza SEVCIKOVA (203 Czech Republic), David ZIHALA (203 Czech Republic), Tereza POPKOVA (203 Czech Republic), Veronika KAPUSTOVA (203 Czech Republic), Lucie BROSKEVICOVA (203 Czech Republic), Lenka CAPKOVA (203 Czech Republic), Lucie ŘÍHOVÁ (203 Czech Republic), Renata BEZDĚKOVÁ (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Vladimir ZIDLIK (203 Czech Republic), Martin HAVEL (203 Czech Republic), Hana PLONKOVA (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Jiri MINARIK (203 Czech Republic), Martin ŠTORK (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Petr PAVLICEK (203 Czech Republic), Ivan SPICKA (203 Czech Republic), Vladimir MAISNAR (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Michal SIMICEK (203 Czech Republic) and Roman HAJEK (203 Czech Republic)

Leukemia, London, Nature Publishing Group, 2022, 0887-6924

English

Článek v odborném periodiku

30205 Hematology

United Kingdom of Great Britain and Northern Ireland

není předmětem státního či obchodního tajemství

URL

RIV/00216224:14110/22:00124970

Faculty of Medicine

000671626300001

daratumumab; multiple myeloma; extramedullary disease; efficacy

14110212, 14110518, rivok

International impact, Reviewed